Default company panoramic image

Marsala Biotech Inc.

Marsala Biotech is developing endostatin gene therapy for the treatment of cancer a huge unmet therapeutic need and commercial opportunity.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Winnipeg, MB, Canada
  • Currency CAD
  • Founded 2010
  • Employees 4
  • Website

Company Summary

Marsala Biotech Inc.'s lead technology E10A, is being evaluated in head and neck cancer patients. Currently there are only 2 FDA approved drugs which have significant drawbacks. Pre-clinical and Phase-I and II clinical trials are complete and a Phase-III clinical trial was initiated in Oct 2013 by Marsala's JV partner in China. Marsala has obtained a SPA from the USFDA and clinical trials are planned for Q1 2016 in Europe and North America.


  • Photo
    President & CEO

    Dr. Thomas has over 18 years of experience in research leadership and strategic planning in the areas of bio-pharma R&D, molecular diagnostics and therapeutic target discovery and validation. In addition, he has been responsible for the scientific evaluation of various opportunities in CentreStone Ventures, a life science focused VC fund. Dr. Thomas has served in senior Executive positions in biopharmaceutical companies in India & Canada.

  • Default avatar
    James Kinley
    Chief Financial Officer

    Mr. Kinley is responsible for the financial operations of Marsala through its contract with Genesys Venture, Inc. Mr.Kinley has extensive experience working with publicaly traded entities, having provided financial reporting services for a number of stock exchange listed real estate investment trusts (REITs) from 2006 to 2008. Mr Kinley is a CA and holds a B.Comm (Honours) degree from the I.H. Asper School of Business (Univ. of Manitoba).

  • Default avatar
    Nancy Stewart
    Director, Clinical Development

    Dr. Nancy Stewart obtained her B.Sc. (Hons.) in human genetics from the University of Manitoba, M.Sc. from McMaster University, and Ph.D from the University of Manitoba. While at the U of M she examined the role of p53 and its control over cell cycle progression. Dr. Stewart has over 15 years' experience in drug development.

  • Default avatar
    Sudha Nair
    Director, Business Development

    Dr. Nair obtained her Masters and PhD in Molecular Biology from University of Southern California, Los Angeles and MBA from University of Western Ontario, Canada. Dr. Nair's postdoctoral training was in stem cell gene therapy at Dana Farber Cancer Institute at Harvard Medical School. Prior to joining Marsala, Dr. Nair was involved in due diligence on business deals and exploring the market space for life science while working at venture firms.

  • Default avatar
    Bob Choy
    Director, Product Development

    Dr. Choy completed his Ph.D. in Biochemistry at the Manitoba Institute of Cell Biology, University of Manitoba. He was an Instructor at Harvard Medical School and at Beth Israel Deaconess Medical Center in Boston, and has held research positions at the NEB Bone and Joint Institute and BIDMC Genomics and Proteomics Group.

Previous Investors

  • Default avatar
    CentreStone Ventures, Winnipeg, MB